Forte Biosciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Forte Biosciences, Inc. (FBRX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-35.48-31.48-13.88-21.71-46.49
Depreciation & Amortization0.040.010.000.040.05
Stock Based Compensation3.103.284.024.210.96
Change in Working Capital1.76-0.391.680.72-3.83
Change in Accounts Payable3.020.270.21-0.29-0.37
Change in Other Working Capital-1.26-0.131.471.01-3.46
Other Operating Activities-0.16-0.134.020.0031.84
Net Cash from Operating Activities-30.75-28.71-8.19-16.68-18.42
Investing Activities
Capital Expenditures-0.04-0.090.000.000.00
Acquisitions0.000.000.000.003.58
Purchases of Investments-35.96-9.970.000.000.00
Sales/Maturities of Investments0.0010.100.000.003.58
Other Investing Activities0.000.000.000.003.58
Net Cash from Investing Activities-35.990.050.000.003.58
Financing Activities
Common Stock Issued53.0025.007.230.0666.96
Common Stock Repurchased0.00-0.060.000.000.00
Other Financing Activities-1.14-0.330.01-0.11-0.29
Net Cash from Financing Activities51.8624.687.24-0.0466.67
Summary
Net Change in Cash-14.88-3.98-0.94-16.7251.83
Cash at Beginning of Period37.1341.1042.0458.776.94
Cash at End of Period22.2437.1341.1042.0458.77
Free Cash Flow-30.78-28.79-8.19-16.68-18.42